The allowed claims within this patent application cover compositions of platelet derived growth factor (PDGF) combined with matrix materials having defined characteristics, which cover the company’s recombinant protein-device combination product candidates, including Augment bone graft and Augment Injectable bone graft.
The new patent will remain in force until 2024, during which time it will prohibit the marketing of similar or generic versions of Augment, Augment Injectable, Gem 21s and potentially other products the company has in development.
In addition to the recently allowed patent application, the company said that it also maintains existing protection through patents that are co-owned with and exclusively licensed from ZymoGenetics and Harvard University. Included among the company’s co-owned and licensed patents are patents that cover PDGF compositions and their use to promote the regeneration of bone, periodontium or ligaments.
Samuel Lynch, president and CEO of BioMimetic Therapeutics, said: “We are excited by the allowance of this patent. Allowance of this patent significantly extends the company’s exclusivity period during which we can realize the full economic benefits of our proprietary PDGF technology platform. Moreover, we have a number of patent applications pending and are optimistic they will lead to additional protection of our technology.”